Angela Casbard

Has grant

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Open

Optimise-FLT3 Study: Optimising therapy for patients with FLT3-mutated Acute Myeloid Leukaemia

Open Date: 2024-03-01

Close Date: 2031-02-01

Grant: Open

SCC-AFTER

Open Date: 2023-01-01

Close Date: 2030-12-01

Grant: Open

The PICCOS trial

Open Date: 2022-11-01

Close Date: 2027-05-01

Grant: Close

FAKTION - A phase 1b/randomised placebo controlled phase II trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor.

Open Date: 2019-01-01

Close Date: 2020-01-01

Grant: Close

CRUK Clinical Trials Unit Funding

Open Date: 2018-10-01

Close Date: 2023-09-01

Articles (12)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

UNITED KINGDOM

View details

ROBERT JONES

Professor

Cardiff University

UNITED KINGDOM

View details

Angela Hassiotis

University College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Angela Casbard

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (12)

Mapping the pathway and support offered to children with an intellectual disability referred to specialist mental health services in the UK

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Remotely Delivered Video Interaction Guidance for Families of Children With an Intellectual Disability Referred to Specialist Mental Health Services: Protocol for a Feasibility Randomized Controlled Trial

Watch Me Play!: protocol for a feasibility study of a remotely delivered intervention to promote mental health resilience for children (ages 0–8) across UK early years and children’s services

Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial

HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.

A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.

Collaborators (7)

Manuel Gomes

Robert Morgan

Lisette Nixon

Richard Adams

Rachel McNamara

ROBERT JONES

Angela Hassiotis

Make your next move.